| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $60,072,728 ) (Continued on the next page) |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270116 | Targeting plasticity in lung cancer | 000 | 3 | NIH | 12/16/2024 | $550,161 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA295658 | Reproducible and Accurate PD-L1 Immunohistochemistry Biomarker Quantification Using Virtual Multiplex Immunofluorescence Restaining | 000 | 1 | NIH | 11/28/2024 | $683,089 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA286330 | Acupuncture to Improve Outcomes in Patients with Sepsis: a Randomized Controlled Trial | 000 | 2 | NIH | 1/23/2025 | $222,156 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA297077 | Metabolic control of malignant fates in lung cancer | 000 | 1 | NIH | 11/27/2024 | $730,400 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA259161 | Uncovering Epigenetic and Transcriptional Drivers of Neuroendocrine Plasticity at Single-Cell Level in Patients with Small Cell Lung Cancer Transformation | 000 | 4 | NIH | 11/15/2024 | $278,198 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AG080684 | Molecular mechanisms of gamma-secretase modulation central to Alzheimer’s disease | 000 | 3 | NIH | 11/15/2024 | $723,560 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AG067598 | Chaperome networks in Alzheimer's disease | 000 | 5 | NIH | 1/23/2025 | $1,033,893 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA286111 | Backup DNA repair in homologous recombination deficient cancers | 000 | 1 | NIH | 11/27/2024 | $487,393 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01DK128615 | Genetic susceptibility to Barrett's esophagus: From GWAS to biology | 000 | 4 | NIH | 11/18/2024 | $751,138 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI150999 | HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome | 000 | 5 | NIH | 2/25/2025 | $688,546 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM152017 | Teaching free energy calculations to learn | 001 | 2 | NIH | 2/25/2025 | $484,704 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA292178 | Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response | 000 | 1 | NIH | 2/24/2025 | $205,700 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 000 | 2 | NIH | 2/18/2025 | $135,224 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K00CA245471 | Investigating the Role of Cell Plasticity in Malignant Transformation | 000 | 6 | NIH | 2/18/2025 | $106,030 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00GM148720 | Molecular mechanisms of memory formation and tolerance in CRISPR-Cas systems | 000 | 3 | NIH | 3/26/2025 | $249,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01GM152667 | Mechanism and Significance of HMG Co-A Synthase 1 Degradation | 000 | 2 | NIH | 3/26/2025 | $330,130 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01CA252048 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | 000 | 5 | NIH | 2/19/2025 | $559,979 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F32CA298730 | Investigating the Role of Mutagenic DNA Repair during the Persistence of Cancer Cells | 000 | 1 | NIH | 2/19/2025 | $79,010 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA250917 | Origins and functions of pancreatic cancer-associated fibroblasts | 000 | 6 | NIH | 3/12/2025 | $338,027 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288692 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma | 001 | 2 | NIH | 3/17/2025 | $501,086 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA251591 | Predicting sensitivity and resistance in RET-driven cancers | 000 | 5 | NIH | 3/17/2025 | $364,399 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA244911 | Targeting stem-like cells and their niche in pancreatic cancer | 000 | 6 | NIH | 3/14/2025 | $441,764 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG1CA233332 | ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC) | 000 | 6 | NIH | 3/12/2025 | $535,627 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG1CA233290 | Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center | 000 | 6 | NIH | 3/13/2025 | $763,821 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288880 | Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer | 000 | 2 | NIH | 3/12/2025 | $362,340 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31CA290899 | Interferon E as a Tumor Suppressor and Potential Therapeutic in Pancreatic Cancer | 000 | 1 | NIH | 3/28/2025 | $48,974 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U24CA285296 | ISIC-REPO; ISIC Skin Imaging Repository Enhancements for Promoting Interoperability and Utilization | 000 | 2 | NIH | 3/13/2025 | $626,533 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08DK125876 | A Targeted Approach to the Surveillance of Precursor Lesions for Gastric Cancer | 000 | 5 | NIH | 4/1/2025 | $167,616 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA248665 | A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer | 000 | 6 | NIH | 3/20/2025 | $576,378 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08DK132518 | Control of Intestinal Epithelial Function through Lymphatic-Intestinal Stem Cell Communication | 001 | 4 | NIH | 2/25/2025 | $167,617 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01NS118067 | Directing Fate, Subtype Identity and Survival in Human Pluripotent-Derived Midbrain Dopamine Neurons | 000 | 5 | NIH | 3/21/2025 | $572,333 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 000 | 5 | NIH | 3/19/2025 | $469,069 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 000 | 4 | NIH | 3/20/2025 | $411,339 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01EB033000 | Multicolor PET to interrogate cancer biology | 000 | 3 | NIH | 3/20/2025 | $605,806 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01NS126921 | Chemical Genetic Dissection of SWI/SNF Chromatin Remodeling Complex Functions in Cerebral Cortex Development | 000 | 3 | NIH | 3/20/2025 | $509,034 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA277464 | Managing metabolic disruption in pancreatic cancer to prevent weight loss and improve quality of life | 001 | 2 | NIH | 2/12/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258736 | A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer | 003 | 6 | NIH | 2/12/2025 | $589,867 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM156454 | Decoding the Ubiquitin and Autophagy Signaling Networks | 000 | 1 | NIH | 1/30/2025 | $440,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA193837 | Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependence | 001 | 10 | NIH | 2/13/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA255655 | Genomic biomarkers of splenic lymphoma | 000 | 6 | NIH | 1/9/2025 | $407,568 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA279922 | Defining the role of GNAS in gastrointestinal metastasis | 000 | 3 | NIH | 2/28/2025 | $268,826 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA270018 | Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer | 001 | 3 | NIH | 2/28/2025 | $586,485 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01FD007544 | Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST) | 002 | 3 | FDA | 3/25/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA276804 | Targeting Pancreatic Cancer Senescence with ImmunoPET | 000 | 2 | NIH | 2/28/2025 | $148,282 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R00HG012973 | Molecular recording to understand the determinants of cell fate transitions in early development | 000 | 3 | NIH | 2/28/2025 | $224,100 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08CA259533 | The role of B-cells in the anti-tumor immune response in triple negative breast cancer | 000 | 4 | NIH | 3/24/2025 | $264,185 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K00CA284294 | Engineering Biomaterials to Modulate the Tumor Immune Microenvironment | 000 | 3 | NIH | 2/14/2025 | $100,760 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA255211 | Targeting immune suppressive microenvironment in ATC | 000 | 5 | NIH | 2/14/2025 | $396,645 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA255336 | Ceramide-Rich Platforms Functionalize Gemcitabine Uptake | 001 | 5 | NIH | 2/14/2025 | $0 |
|
